Cargando…

Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes

BACKGROUND: Resistance to ESAs (erythropoietin stimulating agents) is highly prevalent in hemodialysis patients with diabetes and associated with an increased mortality. The aim of this study was to identify predictors for ESA resistance and to develop a prediction model for the risk stratification...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Andreas, Schneider, Markus P, Scharnagl, Hubert, Jardine, Alan G, Wanner, Christoph, Drechsler, Christiane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614514/
https://www.ncbi.nlm.nih.gov/pubmed/23521816
http://dx.doi.org/10.1186/1471-2369-14-67
_version_ 1782264854333095936
author Schneider, Andreas
Schneider, Markus P
Scharnagl, Hubert
Jardine, Alan G
Wanner, Christoph
Drechsler, Christiane
author_facet Schneider, Andreas
Schneider, Markus P
Scharnagl, Hubert
Jardine, Alan G
Wanner, Christoph
Drechsler, Christiane
author_sort Schneider, Andreas
collection PubMed
description BACKGROUND: Resistance to ESAs (erythropoietin stimulating agents) is highly prevalent in hemodialysis patients with diabetes and associated with an increased mortality. The aim of this study was to identify predictors for ESA resistance and to develop a prediction model for the risk stratification in these patients. METHODS: A post-hoc analysis was conducted of the 4D study, including 1015 patients with type 2 diabetes undergoing hemodialysis. Determinants of ESA resistance were identified by univariate logistic regression analyses. Subsequently, multivariate models were performed with stepwise inclusion of significant predictors from clinical parameters, routine laboratory and specific biomarkers. RESULTS: In the model restricted to clinical parameters, male sex, shorter dialysis vintage, lower BMI, history of CHF, use of ACE-inhibitors and a higher heart rate were identified as independent predictors of ESA resistance. In regard to routine laboratory markers, lower albumin, lower iron saturation, higher creatinine and higher potassium levels were independently associated with ESA resistance. With respect to specific biomarkers, higher ADMA and CRP levels as well as lower Osteocalcin levels were predictors of ESA resistance. CONCLUSIONS: Easily obtainable clinical parameters and routine laboratory parameters can predict ESA resistance in diabetic hemodialysis patients with good discrimination. Specific biomarkers did not meaningfully further improve the risk prediction of ESA resistance. Routinely assessed data can be used in clinical practice to stratify patients according to the risk of ESA resistance, which may help to assign appropriate treatment strategies. CLINICAL TRIAL REGISTRATION: The study was registered at the German medical authority (BfArM; registration number 401 3206). The sponsor protocol ID and clinical trial unique identified number was CT-981-423-239. The results of the study are published and available at http://www.ncbi.nlm.nih.gov/pubmed/16034009.
format Online
Article
Text
id pubmed-3614514
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36145142013-04-03 Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes Schneider, Andreas Schneider, Markus P Scharnagl, Hubert Jardine, Alan G Wanner, Christoph Drechsler, Christiane BMC Nephrol Research Article BACKGROUND: Resistance to ESAs (erythropoietin stimulating agents) is highly prevalent in hemodialysis patients with diabetes and associated with an increased mortality. The aim of this study was to identify predictors for ESA resistance and to develop a prediction model for the risk stratification in these patients. METHODS: A post-hoc analysis was conducted of the 4D study, including 1015 patients with type 2 diabetes undergoing hemodialysis. Determinants of ESA resistance were identified by univariate logistic regression analyses. Subsequently, multivariate models were performed with stepwise inclusion of significant predictors from clinical parameters, routine laboratory and specific biomarkers. RESULTS: In the model restricted to clinical parameters, male sex, shorter dialysis vintage, lower BMI, history of CHF, use of ACE-inhibitors and a higher heart rate were identified as independent predictors of ESA resistance. In regard to routine laboratory markers, lower albumin, lower iron saturation, higher creatinine and higher potassium levels were independently associated with ESA resistance. With respect to specific biomarkers, higher ADMA and CRP levels as well as lower Osteocalcin levels were predictors of ESA resistance. CONCLUSIONS: Easily obtainable clinical parameters and routine laboratory parameters can predict ESA resistance in diabetic hemodialysis patients with good discrimination. Specific biomarkers did not meaningfully further improve the risk prediction of ESA resistance. Routinely assessed data can be used in clinical practice to stratify patients according to the risk of ESA resistance, which may help to assign appropriate treatment strategies. CLINICAL TRIAL REGISTRATION: The study was registered at the German medical authority (BfArM; registration number 401 3206). The sponsor protocol ID and clinical trial unique identified number was CT-981-423-239. The results of the study are published and available at http://www.ncbi.nlm.nih.gov/pubmed/16034009. BioMed Central 2013-03-22 /pmc/articles/PMC3614514/ /pubmed/23521816 http://dx.doi.org/10.1186/1471-2369-14-67 Text en Copyright © 2013 Schneider et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Schneider, Andreas
Schneider, Markus P
Scharnagl, Hubert
Jardine, Alan G
Wanner, Christoph
Drechsler, Christiane
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
title Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
title_full Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
title_fullStr Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
title_full_unstemmed Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
title_short Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
title_sort predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614514/
https://www.ncbi.nlm.nih.gov/pubmed/23521816
http://dx.doi.org/10.1186/1471-2369-14-67
work_keys_str_mv AT schneiderandreas predictingerythropoietinresistanceinhemodialysispatientswithtype2diabetes
AT schneidermarkusp predictingerythropoietinresistanceinhemodialysispatientswithtype2diabetes
AT scharnaglhubert predictingerythropoietinresistanceinhemodialysispatientswithtype2diabetes
AT jardinealang predictingerythropoietinresistanceinhemodialysispatientswithtype2diabetes
AT wannerchristoph predictingerythropoietinresistanceinhemodialysispatientswithtype2diabetes
AT drechslerchristiane predictingerythropoietinresistanceinhemodialysispatientswithtype2diabetes